



June 19th, 2019

This memo is to confirm the participation of Vestra Clinics in the FOCUS study of Teva Pharmaceuticals Evaluating the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients with Inadequate Response to Prior Preventive Treatments. Principal Investigator was Dr. Ladislav Pazdera.

Dr. Pazdera and his team were the highest enrolling site of the study globally, out of 112 clinical sites. The team successfully screened 43 patients for participation in the study and randomized 31 patients.

A total of 112 sites screened 1028 subjects and enrolled 838 subjects globally. Dr. Pazdera site met all study timeline and was significant contributor to the study.

A handwritten signature in blue ink, appearing to read "Melissa Grozinski-Wolff".

Melissa Grozinski-Wolff
Director, Global Clinical Project Management
Teva Branded Pharmaceutical
Products R&D, Inc.
41 Moores Road
Frazer, Pennsylvania 19355
USA

Teva Pharmaceuticals

41 Moores Road, PO Box 4011 | Frazer, PA 19355 | Tel. 610.344.0200 | www.tevapharm.com